about
Glypican-3 Targeting Immunotoxins for the Treatment of Liver CancerThe Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewDectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma.Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyAn IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.Current status of research and treatment for non-small cell lung cancer in never-smoking females.Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studiesAdoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant.The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer.The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.RNA-Seq analysis of interferon inducible p204-mediated network in anti-tumor immunity.Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.Message from the New Editor-in-Chief.
P2860
Q28077270-5FE5A0E0-0602-4745-9A9A-AEA64242485CQ28080338-431E8769-9254-4686-B77C-78DB29441FFCQ37236780-5CCBFFA8-5448-47FE-A0F8-D7CA2925CD4DQ38610333-FD597071-AC3F-4003-85DB-FA0E3048452EQ38730989-015E123E-D383-48A5-BD32-37B15D9BCE26Q38749824-F866D891-429F-49F5-B98E-C03B369565F9Q38749945-BD98D4EF-5C8E-4746-93B8-61EDBF162D94Q39298725-63D129C1-8B3E-4C11-B5E1-D6B606D6494EQ41932624-08087041-326B-4CD1-B8B9-8A2792E3615CQ42378707-D08C741B-549A-4F27-A48F-D81E3367DE0DQ47860410-086175EB-37FD-4DFE-AFC0-47D6874F6A35Q47964658-8F1113EE-6F60-4CE3-8EBC-8CB0E1E6359FQ50033731-C689AC2A-BB0E-46A2-BBE5-B2AFC963A256Q52565481-035DA963-A472-4775-BDDE-C34C809B118DQ52657150-8B81A3E8-EF7A-474A-9426-F9062B8D22EBQ52728758-36E00A5A-8EE3-4937-9C8F-32B4AB400082
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Current status of immunotherapy
@ast
Current status of immunotherapy
@en
Current status of immunotherapy
@nl
type
label
Current status of immunotherapy
@ast
Current status of immunotherapy
@en
Current status of immunotherapy
@nl
prefLabel
Current status of immunotherapy
@ast
Current status of immunotherapy
@en
Current status of immunotherapy
@nl
P2093
P2860
P3181
P356
P1476
Current status of immunotherapy
@en
P2093
Kazuhiro Yoshikawa
Ryuzo Ueda
Susumu Suzuki
P2860
P304
P3181
P356
10.1093/JJCO/HYV201
P407
P577
2016-01-26T00:00:00Z